EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy
Dec 1, 2022, 00:00 AM
10.1016/j.jval.2022.09.710
https://www.valueinhealthjournal.com/article/S1098-3015(22)02914-X/fulltext
Section Title :
Section Order :
10248
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02914-X&doi=10.1016/j.jval.2022.09.710